01 Increasing Adoption of Theranostics in Precision Oncology Theranostics is becoming increasingly important in nuclear medicine by combining molecular imaging with targeted radionuclide therapy within a coordinated treatment pathway. This approach enables clinicians to identify suitable patients, assess disease characteristics, monitor treatment response, and deliver radiation more selectively to targeted tissues. Growing development of radioligand therapies and targeted alpha and beta emitters is expanding the role of nuclear medicine from disease diagnosis toward personalized treatment. In April 2026, industry research identified the growing adoption of theranostics and clinical success of radioligand therapies as major factors supporting nuclear medicine market expansion.
02 Growing Use of PET and SPECT Imaging for Precision Disease Detection Advances in radiotracers are improving the ability to detect tumors, cardiovascular abnormalities, neurological disorders, and other conditions at earlier stages. In July 2026, industry research reported that PET and SPECT remained central to nuclear medicine, with growing use of advanced radiotracers supporting oncology, cardiology, and neurology applications.
01 Rising Demand for Precision Diagnostics and Targeted Therapies Supports Nuclear Medicine Market Growth The increasing prevalence of cancer, cardiovascular diseases, neurological disorders, and other chronic conditions is creating demand for more precise diagnostic and treatment approaches. Nuclear medicine can identify biological and molecular characteristics of disease while targeted radiopharmaceutical therapies can deliver therapeutic radiation to specific disease sites. This combination of accurate diagnosis and personalized treatment is strengthening adoption across hospitals, diagnostic centers, and specialized treatment facilities.
01 High Radiopharmaceutical Production and Infrastructure Costs Can Limit Market Expansion Nuclear medicine requires specialized radiopharmaceutical manufacturing, isotope production facilities, radiation-controlled environments, specialized imaging equipment, and trained personnel. Short radioisotope half-lives also require coordinated production, quality control, transportation, and administration within strict time windows. These requirements increase operating costs and can limit adoption in healthcare systems where specialized infrastructure and financial resources are constrained.
01 Expansion of Radiopharmaceutical Therapies Across Oncology Creates New Growth Opportunities Increasing clinical development of lutetium-177, actinium-225, and other therapeutic isotopes is creating opportunities for new treatment applications and broader adoption of precision oncology.
June 2026 GE HealthCare expanded its nuclear medicine strategy through AI, radiopharmaceutical, and molecular imaging innovations. The initiative focuses on improving precision imaging capabilities and supporting more efficient PET and SPECT workflows.
June 2026 Curium invested more than EUR 32 million in its Saclay, France, operations. The expansion strengthens radiopharmaceutical production capabilities and supports growing demand for nuclear medicine diagnostics and therapies.
January 2026 Siemens Healthineers received U.S. FDA clearance for the Biograph One PET/CT system. The platform integrates advanced imaging performance to support faster examinations and flexible radiopharmaceutical dose administration.
October 2025 Telix Pharmaceuticals expanded its radiopharmaceutical development and commercialization capabilities through strategic investments in nuclear medicine infrastructure. The initiative supports the development and supply of precision diagnostic and therapeutic radiopharmaceuticals.